Merus NV (NASDAQ:MRUS)
| 22.02 Delayed Data As of Jun 24 |  +0.68 / +3.19%Today’s Change | 13.47 Today|||52-Week Range 33.09 | -30.75% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $959.0M |
Company Description
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.
Contact Information
Merus NV Yalelaan 62 Utrecht Utrecht 3584 CM |
Employees
Shareholders
| Other institutional | 41.99% |
| Mutual fund holders | 23.70% |
| Individual stakeholders | 22.29% |
Top Executives
| Bill Lundberg | President, CEO, CFO & Non-Executive Director |
| John de Kruif | Chief Technology Officer & Senior Vice President |
| Ernesto Wasserman | Senior Vice President-Clinical Development |
| Andrew Joe | Chief Medical Officer |
| Cecilia Anna Wilhelmina Geuijen | Chief Scientific Officer & Senior Vice President |
